Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119193) titled 'The efficacy and safety of ivosimod as the first-line treatment for locally advanced or metastatic NSCLC with PD-L1 TPS >= 50%, negative EGFR gene mutation and negative ALK: A multicenter, prospective real-world study' on Feb. 24.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Shanghai pulmonary hospital
Condition:
Lung cancer
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-24
Target Sample Size: Observation Group for Lung Cancer Treatment:485;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj...